The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance.
暂无分享,去创建一个
H. Sørensen | J. Dahlerup | L. Mellemkjær | L. Mellemkjaer | H. Gregersen | L. Thomassen | J. Ibsen | Henrik Gregersen | Jenna Salling Ibsen | Frederik Dahlerup | Lars Thomassen | Henrik Toft Sørensen
[1] 敦 戸川,et al. Monoclonal gammopathy of undetermined significance (MGUS) , 2002 .
[2] P. Simpson,et al. Statistical methods in cancer research , 2001, Journal of surgical oncology.
[3] R. Kyle,et al. Monoclonal gammopathies of undetermined significance. , 2002, Reviews in clinical and experimental hematology.
[4] H. Storm,et al. The Danish Cancer Registry--history, content, quality and use. , 1997, Danish medical bulletin.
[5] M. Dimopoulos,et al. Prognostic features of asymptomatic multiple myeloma , 1997, British journal of haematology.
[6] T. Zemunik,et al. Prognosis in monoclonal gammopathy of undetermined significance , 1997, British journal of haematology.
[7] R. Casale,et al. Risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. , 1997, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[8] R. Casale,et al. The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases. , 1997, Acta haematologica.
[9] L. Baldini,et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. , 1996, Blood.
[10] J. Coebergh,et al. Malignant transformation of monoclonal gammopathy of undetermined significance among out‐patients of a community hospital in Southeastern Netherlands , 1995, British journal of haematology.
[11] M. Raymond,et al. Monitoring of monoclonal gammopathies: rational use of densitometry and rate nephelometry. , 1994, Clinical biochemistry.
[12] R A Kyle,et al. "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up. , 1993, Mayo Clinic proceedings.
[13] A. López-Guillermo,et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance , 1992, British journal of haematology.
[14] J. Bergua,et al. [Monoclonal gammopathies of undetermined significance. Clinical course and biological aspects of 397 cases]. , 1991, Sangre.
[15] R. Casale,et al. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications. , 1991, Panminerva medica.
[16] R. Kyle,et al. The spectrum of IgM monoclonal gammopathy in 430 cases. , 1987, Mayo Clinic proceedings.
[17] Norman E. Breslow,et al. The design and analysis of cohort studies , 1987 .
[18] E. Schmidt,et al. Diagnostic value of the concentration of M-component in initial classification of monoclonal gammopathy. , 2009, Scandinavian journal of haematology.
[19] S. Clejan,et al. Long-term study of gammopathies. Clinically benign cases showing transition to malignant plasmacytomas after long periods of observation. , 1986, Clinical biochemistry.
[20] M. Vicariot,et al. Monoclonal gammopathies in the adult population of Finistère, France. , 1982, Journal of clinical pathology.
[21] A. Carter,et al. The Physiopathological Significance of Benign Monoclonal Gammopathy: a Study of 64 Cases , 1980, British journal of haematology.
[22] B G Johansson,et al. Agarose gel electrophoresis. , 1972, Scandinavian journal of clinical and laboratory investigation. Supplementum.
[23] U. Axelsson,et al. Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. , 2009, Acta medica Scandinavica.
[24] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .